These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 36403197)

  • 1. TTI1 promotes non-small-cell lung cancer progression by regulating the mTOR signaling pathway.
    Zhang LX; Yang X; Wu ZB; Liao ZM; Wang DG; Chen SW; Lu F; Wu YB; Zhu SQ
    Cancer Sci; 2023 Mar; 114(3):855-869. PubMed ID: 36403197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OTUB2 stabilizes U2AF2 to promote the Warburg effect and tumorigenesis via the AKT/mTOR signaling pathway in non-small cell lung cancer.
    Li J; Cheng D; Zhu M; Yu H; Pan Z; Liu L; Geng Q; Pan H; Yan M; Yao M
    Theranostics; 2019; 9(1):179-195. PubMed ID: 30662561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer.
    Yin C; Lin X; Wang Y; Liu X; Xiao Y; Liu J; Snijders AM; Wei G; Mao JH; Zhang P
    Cell Oncol (Dordr); 2020 Jun; 43(3):395-407. PubMed ID: 32006253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
    Lu C; Shan Z; Hong J; Yang L
    Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UBQLN4 promotes the proliferation and invasion of non-small cell lung cancer cell by regulating PI3K/AKT pathway.
    He L; Chen H; Ruan B; He L; Luo M; Fu Y; Zou R
    J Cancer Res Clin Oncol; 2024 Jul; 150(7):335. PubMed ID: 38969831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting SNORA38B attenuates tumorigenesis and sensitizes immune checkpoint blockade in non-small cell lung cancer by remodeling the tumor microenvironment via regulation of GAB2/AKT/mTOR signaling pathway.
    Zhuo Y; Li S; Hu W; Zhang Y; Shi Y; Zhang F; Zhang J; Wang J; Liao M; Chen J; Qian H; Li D; Sun C
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35577506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD151 drives cancer progression depending on integrin α3β1 through EGFR signaling in non-small cell lung cancer.
    Zhu J; Cai T; Zhou J; Du W; Zeng Y; Liu T; Fu Y; Li Y; Qian Q; Yang XH; Li Q; Huang JA; Liu Z
    J Exp Clin Cancer Res; 2021 Jun; 40(1):192. PubMed ID: 34108040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of eIF3C Overexpression in Predicting Prognosis of Intrahepatic Cholangiocarcinoma.
    Xu YP; Dong ZN; Zhou YQ; Zhao YJ; Zhao Y; Wang F; Huang XY; Guo CY
    Dig Dis Sci; 2022 Feb; 67(2):559-568. PubMed ID: 33576946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tastin promotes non-small-cell lung cancer progression through the ErbB4, PI3K/AKT, and ERK1/2 pathways.
    Yue A; Chen M; Dai S; Zhang Y; Wei W; Fan L; Wang F; Zhang F; Yu H; Lu Y; Lei Y
    Exp Biol Med (Maywood); 2023 Mar; 248(6):519-531. PubMed ID: 36691332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FKBP4 Accelerates Malignant Progression of Non-Small-Cell Lung Cancer by Activating the Akt/mTOR Signaling Pathway.
    Meng W; Meng J; Jiang H; Feng X; Wei D; Ding Q
    Anal Cell Pathol (Amst); 2020; 2020():6021602. PubMed ID: 33354489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plakophilin-2 accelerates cell proliferation and migration through activating EGFR signaling in lung adenocarcinoma.
    Hao XL; Tian Z; Han F; Chen JP; Gao LY; Liu JY
    Pathol Res Pract; 2019 Jul; 215(7):152438. PubMed ID: 31126818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel long non-coding RNA LBX2-AS1 indicates poor prognosis and promotes cell proliferation and metastasis through Notch signaling in non-small cell lung cancer.
    Tang LX; Su SF; Wan Q; He P; Xhang Y; Cheng XM
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(17):7419-7429. PubMed ID: 31539129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression Signature and Role of miR-30d-5p in Non-Small Cell Lung Cancer: a Comprehensive Study Based on in Silico Analysis of Public Databases and in Vitro Experiments.
    Gao L; He RQ; Wu HY; Zhang TT; Liang HW; Ye ZH; Li ZY; Xie TT; Shi Q; Ma J; Hu XH; Chen G
    Cell Physiol Biochem; 2018; 50(5):1964-1987. PubMed ID: 30396166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DDX5 promotes proliferation and tumorigenesis of non-small-cell lung cancer cells by activating β-catenin signaling pathway.
    Wang Z; Luo Z; Zhou L; Li X; Jiang T; Fu E
    Cancer Sci; 2015 Oct; 106(10):1303-12. PubMed ID: 26212035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hsa_circ_0016760 exacerbates the malignant development of non‑small cell lung cancer by sponging miR‑145‑5p/FGF5.
    Zhu Z; Wu Q; Zhang M; Tong J; Zhong B; Yuan K
    Oncol Rep; 2021 Feb; 45(2):501-512. PubMed ID: 33416186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysregulated
    Sui J; Zhao Q; Zhang Y; Liang G
    DNA Cell Biol; 2022 Mar; 41(3):319-329. PubMed ID: 35244469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
    Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
    Gene; 2019 May; 698():50-60. PubMed ID: 30822475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 19. LncRNA MALAT1 promotes migration and invasion of non-small-cell lung cancer by targeting miR-206 and activating Akt/mTOR signaling.
    Tang Y; Xiao G; Chen Y; Deng Y
    Anticancer Drugs; 2018 Sep; 29(8):725-735. PubMed ID: 29916897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mTOR and PTEN expression in non-small cell lung cancer: analysis by real-time fluorescence quantitative polymerase chain reaction and immunohistochemistry.
    Wang L; Yue W; Zhang L; Zhao X; Wang Y; Xu S
    Surg Today; 2012 May; 42(5):419-25. PubMed ID: 22127531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.